Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study

Ruvim Izikson, Daniel Brune, Jean-Sébastien Bolduc, Pierre Bourron, Marion Fournier, Tamala Mallett Moore, Aseem Pandey, Lucia Perez, Nessryne Sater, Anju Shrestha, Sophie Wague, Sandrine I Samson
doi: https://doi.org/10.1101/2021.10.29.21265248

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Back to top
Posted October 29, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study
Ruvim Izikson, Daniel Brune, Jean-Sébastien Bolduc, Pierre Bourron, Marion Fournier, Tamala Mallett Moore, Aseem Pandey, Lucia Perez, Nessryne Sater, Anju Shrestha, Sophie Wague, Sandrine I Samson
medRxiv 2021.10.29.21265248; doi: https://doi.org/10.1101/2021.10.29.21265248
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area